

PTO/SB/08A (04-03)  
Approved for use through 04/30/2003. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 4

Complete if Known

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1841 1644
Examiner Name	/Marianne DiBrino
Attorney Docket Number	020054-002310US

RECEIVED  
AUG 25 2003  
TECH CENTER 1600/2500

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
MD	A1	US-5,632,994		05/27/97	Reed et al.	
MD	A2	US-5,747,245		05/05/98	Reed et al.	
MD	A3	US-5,876,939		03/02/99	Reed et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MD	B1	PCT	WO 98/05347	A1	02-12-1998	Sato et al.		<input type="checkbox"/>
	B2	PCT	WO 98/23781	A1	06-04-1998	Li et al.		<input type="checkbox"/>
	B3	PCT	WO 98/40407	A1	09-17-1998	Worley et al.		<input type="checkbox"/>
	B4	PCT	WO 99/03974	A1	01-28-1999	Zucker et al.		<input type="checkbox"/>
	B5	PCT	WO 99/07846	A1	02-18-1999	Eynabashi et al.		<input type="checkbox"/>
	B6	PCT	WO 00/15794	A1	03-23-2000	Jue et al.		<input type="checkbox"/>
	B7	PCT	WO 00/31124	A2	06-02-2000	Lin et al.		<input type="checkbox"/>
	B8	PCT	WO 00/48002	A1	08-17-2000	Spilantini et al.		<input type="checkbox"/>
	B9	PCT	WO 00/69897	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>
MD	B10	PCT	WO 00/69898	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>

Examiner  
Signature

/Marianne DiBrino/

Date  
Considered


07/31/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 7449

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 2 of 4

### Complete If Known

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	4644 1644
Examiner Name	/Marianne DiBrino/
Attorney Docket Number	020054-002310US

RECEIVED  
AUG 25 2003  
TECH CENTER 16012500

### NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MD	C1	Altin, J. and Sloan, E. "The role of CD45 and CD45-associated molecules in T cell activation" <i>Immunology and Cell Biology</i> , 1997, pp. 430-445, Vol. 75.	
	C2	Bals, R. et al. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide", <i>Infection and Immunity</i> , November 1999, pp. 6084-6089, Vol. 67, No. 11.	
	C3	Barday, A., et al., "The Leucocyte Antigen Factsbook", <i>Harcourt Braces &amp; Company</i> , page 363, (1997).	
	C4	Bruyns, E. et al. "Identification of the Sites of Interaction between Lymphocyte Phosphatase-associated Phosphoprotein (LPAP) and CD45", <i>Journal of Biological Chemistry</i> , December 29, 1996, pp. 31372-31376, Vol. 270, No. 52, U.S.A.	
	C5	Cherukuri, A. et al. "Floating the raft hypothesis: lipid rafts play a role in immune cell activation", <i>Immunity</i> , June 2001, pp.657-660, Vol. 14, Cell Press.	
	C6	Ding, I. Et al., "Biochemical and Functional Analysis of Mice Deficient in Expression of the CD45-Associated Phosphoprotein LPAP", <i>European Journal of Immunology</i> , 29(12):3956-61 (1999).	
	C7	Doyle, D. A., et al., "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ", <i>Cell</i> , 85(7):1067-76, (1996).	
	C8	Faulkner, G. et al. "A New Z-band Alternatively Spliced PDZ-motif Protein." <i>The Journal of Cell Biology</i> , July 26, 1999; pp. 465-475, Vol. 146, No. 2.	
	C9	Gardioli, D. et al. "Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation", <i>Oncogene</i> , 18(40):5487-5496, (1999).	
	C10	Gee, S.H. et al., "Interaction of Muscle and Brain Sodium Channels with Multiple Members of the Syntrophin Family of Dystrophin-Associated Proteins", <i>J. Neuroscience</i> , 18(1):128-137, (1998).	
	C11	Gee, S.H., et al., "Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains", <i>The Journal of Biological Chemistry</i> , 273(34):21980-21987, (1998).	
	C12	Hanada, T., et al., "Human Homologue of the Drosophila Discs Large Tumor Suppressor Binds to p56 <sup>lck</sup> Tyrosine Kinase and Shaker Type Kv1.3 Potassium Channel in T. Lymphocytes", <i>The Journal of Biological Chemistry</i> , 272(43):26899-26904, (1997).	
MD	C13	Kiyono, T. et al. "Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the <i>Drosophila</i> discs large tumor suppressor protein", <i>Proc. Natl. Acad. Sci.</i> , October 1997, pp. 11612-11616, Vol. 94, U.S.A.	

Examiner Signature	07/31/2006	Date Considered	07/31/2006
--------------------	------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1244 (P. 681M)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of 4

**C mplete if Known**

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644-1699
Examiner Name	/Marianne DiBrino
Attorney Docket Number	020054-002310US

TECH CENTER 16002500  
AUG 23 2003

RECEIVED

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MD	C14	Kobayashi, I., et al., "Identification of an Autoimmune Enteropathy-related 75-kilodalton Antigen", <i>Gastroenterology</i> , October 1999, pp. 823-830, Vol. 117, No. 4.
	C15	Maekawa, K., et al., "Association of Protein-Tyrosine Phosphatase PTP-BAS with the Transcription-factor-inhibitory Protein IxBa Through Interaction Between the PDZ1 Domain and Ankyrin Repeats", <i>Biochemical Journal</i> , 337(2):179-187, (1999).
	C16	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain", <i>DNA Research</i> , 1996, pp. 321-329, Vol. 3.
	C17	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain (Supplement)", <i>DNA Research</i> , 1996, pp. 341-354, Vol. 3, Supplement.
	C18	Nishihara, H. et al. "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins", <i>Biochimica et Biophysica Acta</i> , 1999, pp. 179-187, Elsevier Publishing.
	C19	Nishihara, H. "Analysis of Hematopoietic Cell Specific Protein, M-DOCK", <i>Hokkaido Igaku Zasshi</i> , March 1999, p. 157-166, Vol. 74, No. 2.
	C20	Patel, V. et al., "A Molecular Framework for 2-Step T Cell Signaling: Lck Src Homology 3 Mutations Discriminate Distinctly Regulated Lipid Raft Reorganization Events", <i>Journal of Immunology</i> , 166(2):754-64 (2001).
	C21	Reynaud, C. et al., "The PDZ Protein TIP-1 Interacts with the Rho Effector Rhotekin and Is Involved in Rho Signaling to the Serum Response Element", <i>The Journal of Biological Chemistry</i> , 275(43):33962-33968, (2000).
	C22	Rousset, R., et al., "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins", <i>Oncogene</i> , 16(5):643-54, (1998).
	C23	Saras, J., et al., "PDZ Domains Bind Carboxy-Terminal Sequences of Target Proteins", <i>Tibs Trends in Biochemical Sciences</i> , en, Elsevier Publication, Cambridge, 21(12):455-458, (1996).
	C24	Schepens, J., et al., "The Neuronal Nitric Oxide Synthase PDZ Motif Binds to -G(D.E)XV Carboxy Terminal Sequences", <i>Febs Letters</i> , 409(1-2):53-56, (1997).
MD	C25	Shibuya, A., et al., "DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes", <i>Immunity</i> , 4:573-581, (1996).


Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
--------------------	--------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

47111933 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449 (03-04)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 4 of 4

**Complete if Known**

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	<del>1041</del> 1644
Examiner Name	/Marianne DiBrino/
Attorney Docket Number	020054-002310US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MD	C26	Shibuya, A., et al., "Protein Kinase C is Involved in the Regulation of Both Signaling and Adhesion Mediated by DNAX Accessory Molecule-1 Receptor", <i>The Journal of Immunology</i> , 161:1671-1676, (1998).	
	C27	Shibuya, K., et al., "Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule", <i>Immunity</i> , 11:615-623, (1999).	
	C28	Suzuki, T., et al., "Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control", <i>Oncogene</i> , 18(44):5967-72, (1999).	
	C29	Vallénus, T. et al. "CLP-36 PDZ-LIM Protein Associates with Nonmuscle alpha-Actinin-1 and alpha-Actinin-4." <i>The Journal of Biological Chemistry</i> , April 14, 2000; pp. 11100-11105, Vol. 275, No. 15.	
	C30	Wechsler, A. et al. "Brain Spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin." <i>The EMBO Journal</i> , 1998, pp. 3931-3939, Vol. 17, No. 14.	
	C31	Xia, H. et al. "Actinin-associated LIM Protein: Identification of a Domain Interaction between PDZ and Spectrin-like Repeat Motifs", <i>The Journal of Cell Biology</i> , October 1997, pp. 507-515, Vol. 139, No. 2.	
	C32	Yanagisawa, J., et al., "The Molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis", <i>J. Biol. Chem.</i> , 272(13):8539-8545, (1997).	
	C33	GenBank, Accession Number BM845132, 03/06/2002	
	C34	GenBank, Accession Number CB131761, 01/29/2003	
	C35	GenBank, Accession Number CB961389, 04/28/2003	
	C36	GenBank, Accession Number CB995033, 04/30/2003	
	C37	Genbank, Accession Number D86964, 02/07/1999	
	C38	OMIM Database entry entitled, '147138 Fc Fragment of IgE, High Affinity I, Receptor for, Beta Subunit; FCER1B', <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispim?147138">www.ncbi.nlm.nih.gov/htbin-post/Omim/dispim?147138</a> , 08/27/1992 Victor A. McKusick.	
MD	C39	OMIM Database entry entitled, "603122 Dedicator of Cytokinesis 2; Dock 2" <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispim?603122">www.ncbi.nlm.nih.gov/htbin-post/Omim/dispim?603122</a> , 10/12/1998 Rebekah S. Rasooly.	

Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/080,273
				Filing Date	February 19, 2002
				First Named Inventor	Lu, Peter S.
				Art Unit	1644
				Examiner Name	Dibrino, Marianne
Sheet	1	of	1	Attorney Docket Number	020054-002310US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-			
	A2	US-			


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1							<input type="checkbox"/>
	B2							<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MD	C1	Coligan, John et al. "Antibody Detection and Preparation" <u>Current Protocols in Immunology, Supplement 1</u> , 1991, pp. 2.0.1-2.1.18.	
MD	C2	GenBank, Accession Number AF028823, 12/01/1999	
MD	C3	Schraven, Burkhardt et al. "LPAP, a Novel 32-kDa Phosphoprotein That Interacts With CD45 in Human Lymphocytes", <i>J. Biological Chemistry</i> , Nov. 18, 1994; pp. 29102-29111, Vol. 269, No. 46.	

Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/080,273		
		Filing Date	February 19, 2002		
		First Named Inventor	Lu, Peter S.		
		Art Unit	1644		
		Examiner Name	Dibrino, Marianne		
Sheet	1	of	1	Attorney Docket Number	020054-002310US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MD	C1	BURGESS, WILSON H. et al. "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" Journal of Cell Biology, Nov. 1990, pp. 2129-2138, Vol. 111, The Rockefeller University Press.	
MD	C2	LAZAR, ELIANE et al. "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" Molecular and Cellular Biology, March 1988, pp. 1247-1252, Vol. 8, No. 3.	
MD	C3	MIKAYAMA, TOSHIFUMI et al. "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor" Proc. Natl. Acad. Sci., Nov. 1993, pp. 10056-10060, Vol. 90.	

Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
-----------------------	--------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/080,273
		Filing Date	February 19, 2002
		First Named Inventor	Lu, Peter S.
		Art Unit	1644
		Examiner Name	Dibrino, Marianne
Sheet 1 of 1	Attorney Docket Number	020054-002310US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-			
	A2	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MD	B1	PCT	WO 00/69896	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>
MD	B2	PCT	WO 02/42422	A2	05-30-2002	Arbor Vita Corp		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C1			
	C2			
	C3			

Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
--------------------	--------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-03)

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/080,273
Filing Date		February 19, 2002			
First Named Inventor		Lu, Peter S.			
Art Unit		1644			
Examiner Name		Dibrino, Marianne			
Attorney Docket Number		020054-002310US			
Sheet	1	of	2		

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MD	A1	US-5,863,898	01-26-1999	Goli et al.	
	A2	US-5,958,731	09-28-1999	Yue et al.	
	A3	US-5,976,819	11-02-1999	Finkel et al.	
	A4	US-6,174,702 B1	01-16-2001	Lal et al.	
	A5	US-2002/0058607 A1	05-16-2002	Sato et al.	
	A6	US-2002/0147306 A1	10-10-2002	Lin et al.	
MD	A7	US 2003/0203414 A1	10-30-2003	Sato et al.	
	A8				

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MD	B1	PCT	WO 02/31512	A2	04-18-2002	Arbor Vita Corp		<input type="checkbox"/>
MD	B2	PCT	WO 03/014303	A2	02-20-2003	Arbor Vita Corp		<input type="checkbox"/>
MD	B3	CA	2,273,622	A1	12-02-2000	Tymiansky M.		<input type="checkbox"/>

Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/080,273
		Filing Date	February 19, 2002
		First Named Inventor	Lu, Peter S.
		Art Unit	1644
		Examiner Name	Dibrino, Marianne
Sheet 2 of 2	Attorney Docket Number	020054-002310US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MD	C1	BRENMAN et al. "Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains." Cell, 1996, pp. 757-767, Vol. 84, No. 5	
	C2	FABRE, STÉPHANE et al. "Identification of functional PDZ domain binding sites in several human proteins" Molecular Biology Reports, 2000, pp. 217-224, Vol. 27, No. 4.	
	C3	FORD, KG et al. "Protein transduction: an alternative to genetic intervention?" Gene Therapy, 2001, pp. 1-4, Vol. 8, Nature Publishing Group.	
	C4	HARRIS, BARUCH Z. & LIM, WENDELL A. "Mechanism and role of PDZ domains in signaling complex assembly" Signal Transduction and Cellular Organization, Journal of Cell Science, 2001, pp. 3219-3231, Vol. 114.	
	C5	KORNAU et al. "Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95." Science, 1995, pp. 1737-1740, Vol. 269, No. 5231.	
	C6	LEE, SIU SYLVIA et al. "Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein" Proceedings of the Nat. Acad. Of Sci. USA, June 1997, pp. 6670-6675, Vol. 94.	
	C7	MARFATIA, SHIRIN et al. "The PDZ domain of human erythrocyte p55 mediates its binding to the cytoplasmic carboxy terminus of Glycophorin C" The Journal of Biological Chemistry, September 1997, pp. 24191-24197, Vol. 272, No. 39	
	C8	NIETHAMMER, MARTIN et al. "CRIPT, a Novel Postsynaptic Protein that Binds to the Third PDZ Domain of PSD-95/SAP90" Neuron, April 1998, pp. 693-707, Vol. 20, Cell Press.	
MD	C9	SONGYANG, Z. ET AL. "Recognition of Unique Carboxyl-Terminal Motifs by Distinct PDZ Domains" Science, 3 January 1997, pp. 73-77, Vol. 275.	
	C10	WANG, YU TIAN et al. "Ca <sup>2+</sup> -Independent reduction of N-methyl-D-aspartate channel activity by protein tyrosine phosphatase" PNAS USA, Feb. 1996, pp. 1721-1725, Vol. 93.	
	C11		

Examiner Signature	/Marianne DiBrino/	Date Considered	07/31/2006
--------------------	--------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.